Malignant Pleural Mesotheliomas
3 clinical trials · Condition
◉ Watch Malignant Pleural Mesotheliomas
| Record | Firm | Date |
|---|---|---|
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma (NCT07510815) | Beijing Biotech | 2026-03-02 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas (NCT03233724) | National Cancer Institute (NCI) | 2018-04-11 |
| Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) (NCT02603315) | Ain Shams University | 2015-10-01 |
Track Malignant Pleural Mesotheliomas automatically
Every clearance here is in the API, with alerts when new ones post.